Victor Asua

Victor Asua

Auto-generated profile, based on publicly available information

Victor Asua

Infectious Diseases Research Collaboration, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
VAVictor Asua
Victor Asua
MCMelissa D Conrad
Melissa D Conrad
OAOzkan Aydemir
Ozkan Aydemir
MDMarvin Duvalsaint
Marvin Duvalsaint
JLJennifer Legac
Jennifer Legac
PRPhilip J Rosenthal
Philip J Rosenthal
In Uganda, artemether-lumefantrine is recommended for malaria treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug resistance may limit efficacies. Genetic polymorphisms associated with sensitivities to key drugs were characterized in samples collected from 16 sites across Uganda in 2018 and 2019 by ligase detection reaction fluorescent microsphere, molecular inversion probe, dideoxy sequencing, and quantitative polymerase chain reaction assays. Considering transporter polymorphisms associated with resistance to aminoquinolines, the prevalence of Plasmodium falciparum chloroquine resistance transporter (PfCRT) 76T decreased, but varied markedly between sites (0–46% in 2018; 0–23% in 2019); additional PfCRT polymorphisms and plasmepsin-2/3 amplifications associated elsewhere with resistance to piperaquine were not seen. For P. falciparum multidrug resistance protein 1, in 2019 the 86Y mutation was absent at all sites, the 1246Y mutation had prevalence ≤20% at 14 of 16 sites, and gene amplification was not seen. Considering mutations associated with high-level sulfadoxine-pyrimethamine resistance, prevalences of P. falciparum dihydrofolate reductase 164L (up to 80%) and dihydropteroate synthase 581G (up to 67%) were high at multiple sites. Considering P. falciparum kelch protein propeller domain mutations associated with artemisinin delayed clearance, prevalence of the 469Y and 675V mutations has increased at multiple sites in northern Uganda (up to 23% and 41%, respectively). We demonstrate concerning spread of mutations that may limit efficacies of key antimalarial drugs.

6 February 2024 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
PRPhilip J. Rosenthal
Philip J. Rosenthal
VAVictor Asua
Victor Asua
MCMelissa D. Conrad
Melissa D. Conrad

1 March 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
VAVictor Asua
Victor Asua
JVJoanna Vinden
Joanna Vinden
MCMelissa D. Conrad
Melissa D. Conrad
JLJennifer Legac
Jennifer Legac
SKSimon P. Kigozi
Simon P. Kigozi
PRPhilip J. Rosenthal
Philip J. Rosenthal
The potential spread of antimalarial drug resistance to Africa, in particular for artemisinins and key partner drugs, is a major concern. We surveyed Plasmodium falciparum genetic markers associated with drug sensitivity on 3 occasions at ∼6 month intervals in 2016-17 at 10 sites representing a range of epidemiological settings in Uganda. For putative drug transporters, we found continued evolution toward wild type sequences associated with increased sensitivity to chloroquine. For pfcrt K76T, by 2017 the prevalence of wild type was >60% at all sites, and >90% at 6 sites. For the pfmdr1 N86Y and D1246Y alleles, wild type prevalence ranged from 80-100%. We found low prevalence of K13 propeller domain mutations, which are associated with artemisinin resistance in Asia, but one mutation previously identified in northern Uganda, 675V, was seen in 2.0% of samples, including 5.5% from the 3 northernmost sites. Amplification of the pfmdr1 and plasmepsin2 genes, associated elsewhere with decreased sensitivity to lumefantrine and piperaquine, respectively, was seen in <1% of samples. For the antifolate targets pfdhfr and pfdhps, 5 mutations previously associated with resistance were very common, and the pfdhfr 164L and pfdhps 581G mutations associated with higher-level resistance were seen at multiple sites, although prevalence did not clearly increase over time. Overall, changes were consistent with the selective pressure of the national treatment regimen, artemether-lumefantrine, with increased sensitivity to chloroquine, and with poor efficacy of antifolates. Strong evidence for resistance to artemisinins was not seen. Continued surveillance of markers that predict antimalarial drug sensitivity is warranted.

7 September 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
VAVictor Asua
Victor Asua
LMLevicatus Mugenyi
Levicatus Mugenyi
PRPhilip J. Rosenthal
Philip J. Rosenthal
SNSamuel L. Nsobya
Samuel L. Nsobya
JNJoaniter I. Nankabirwa
Joaniter I. Nankabirwa
MCMelissa Conrad
Melissa Conrad
Contributions of species other than Plasmodium falciparum to human malaria in sub-Saharan Africa are uncertain. We collected blood from children aged 6 months to 10 years diagnosed with malaria by Giemsa-stained blood smears (176 subjects) or histidine rich protein-2-based rapid diagnostic tests (323 subjects) in 2016; 50 samples from each of 10 sites across Uganda were studied to identify infecting species. Of 499 available samples, 474 demonstrated plasmodial infection by polymerase chain reaction amplification of 18S ribosomal RNA genes, including P. falciparum in 472, Plasmodium malariae in 22, Plasmodium ovale in 15, and Plasmodium vivax in four; 435 were pure P. falciparum, two did not contain P. falciparum, and the remainder were mixed infections including P. falciparum. The prevalence of nonfalciparum species varied geographically. Stratifying based on recent history of indoor residual spraying (IRS) of insecticides, nonfalciparum infections were seen in 27/189 (14.8%) samples from sites that received and 13/285 (4.6%) samples from sites that did not receive IRS since 2010 (P = 0.0013). Overall, 39/474 (8.2%) samples from individuals diagnosed with malaria included nonfalciparum infections. Thus, a substantial proportion of episodes of malaria in Uganda include infections with plasmodial species other than P. falciparum.

17 November 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
PNPatience Nayebare
Patience Nayebare
VAVictor Asua
Victor Asua
MCMelissa D. Conrad
Melissa D. Conrad
RKRichard Kajubi
Richard Kajubi
AKAbel Kakuru
Abel Kakuru
PRPhilip J. Rosenthal
Philip J. Rosenthal
Intermittent preventive treatment in pregnancy (IPTp) with monthly sulfadoxine-pyrimethamine (SP) is recommended for malaria-endemic parts of Africa, but efficacy is compromised by resistance and, in recent trials, dihydroartemisinin-piperaquine (DP) has shown better antimalarial protective efficacy. We utilized blood samples from a recent trial to evaluate selection by IPTp with DP or SP of Plasmodium falciparum genetic polymorphisms that alter susceptibility to these drugs. The prevalence of known genetic polymorphisms associated with altered drug susceptibility was determined in parasitemic samples, including 375 collected before IPTp drugs were administered, 125 randomly selected from those receiving SP, and 80 from those receiving DP. For women receiving DP, the prevalence of mixed/mutant sequences was greater in samples collected during IPTp compared to that in samples collected prior to the intervention for PfMDR1 N86Y (19.7% vs. 4.1%, p<0.001), PfMDR1 Y184F (73.7% vs. 53.6%, p=0.002), and PfCRT K76T (45.6% vs. 24.4%, p=0.002). Considering SP, prior to IPTp the prevalence of all 5 common antifolate mutations was over 92%, and this prevalence increased following exposure to SP, although none of these changes were statistically significant. The prevalence of two additional mutations associated with high-level SP resistance was greater, but not significantly so, in samples collected during IPTp compared to those collected before the intervention (PfDHFR 164L: 9.3% vs. 3.9%, p=0.07; PfDHPS 581G: 3.4% vs. 2.9%, p=0.73). Use of IPTp in Uganda selected for parasites with mutations associated with decreased susceptibility to IPTp regimens. Thus, a potential drawback of IPTp is selection of parasites with decreased drug susceptibility.

18 January 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
MKMariko Kanai
Mariko Kanai
TYTomas Yeo
Tomas Yeo
VAVictor Asua
Victor Asua
PRPhilip J. Rosenthal
Philip J. Rosenthal
DFDavid A. Fidock
David A. Fidock
SMSachel Mok
Sachel Mok
Research efforts to combat antimalarial drug resistance rely on quick, robust, and sensitive methods to genetically characterize Plasmodium falciparum parasites. We developed a single-nucleotide polymorphism (SNP)-based genotyping method that can assess 33 drug resistance-conferring SNPs in dhfr, dhps, pfmdr1, pfcrt, and k13 in nine PCRs, performed directly from P. falciparum cultures or infected blood.